New research published in The Lancet has shed light on a complex relationship between obesity and cardiovascular health in an era where millions are taking medication to lower blood pressure and cholesterol levels. While it is well-established that being obese increases the risk of heart attacks and strokes, this study challenges assumptions about how much this risk is reduced by modern medications.
Researchers drew on data from 110 health datasets covering almost one million participants across seven high-income countries, including England, to investigate blood pressure and cholesterol levels in individuals with varying Body Mass Index (BMI) classifications. The analysis spanned over three decades, from 1990 to 2024, offering valuable insights into how these risks have evolved.
The study aimed to answer key questions about the impact of obesity on cardiovascular health, including how it compares to having a normal BMI or being overweight. It also explored whether younger and older age groups experience different levels of risk, and whether medication use has altered this landscape over time.
Experts involved in discussing the study's findings included Professor Majid Ezzati from Imperial College London, Professor Edward Gregg from RCSI University of Medicine and Health Sciences, and Dr Francesco Zaccardi from the University of Leicester. Their analysis highlighted the intricate interplay between obesity, medication use, and long-term cardiovascular outcomes.
The implications of this study are significant for understanding the current state of cardiovascular health among individuals with obesity. It also raises questions about the potential impact of new obesity drugs on these health trajectories, underscoring the need for ongoing research in public health to stay ahead of evolving risks and interventions.